Patents Assigned to Viragen, Inc.
  • Publication number: 20080120732
    Abstract: The present invention provides an improved method for achieving efficient transcription and translation of modified transgene constructs in vector systems. The vector may be a lentiviral vector. Such a method facilitates the production of viral vector genomes with intact functional transgene sequences allowing stable integration of a transgene-containing viral vector genome into the germline of an animal such as a transgenic avian. The subsequent expression of the transgene results in a recombinant protein product being produced, which, in the case of a transgenic avian can result in the targeted production of the protein into the egg of the transgenic bird.
    Type: Application
    Filed: September 2, 2005
    Publication date: May 22, 2008
    Applicant: Viragen Inc.
    Inventor: Elizabeth Elliot
  • Publication number: 20060280723
    Abstract: The present invention provides a composition and method for use in the prevention or treatment of a coronaviral infection and in particular, the human coronavirus infection termed severe acute respiratory syndrome (SARS) coronavirus (SARS-HCoV). A method of treating a coronaviral infection is provided through the administration of interferon, further the use of interferons in the treatment of a coronaviral infection is also provided. Preferred forms of interferon for use in the invention are multi-subtype interferon products such as multi-subtype, human alpha-interferon derived from white blood cells commercially available as Multiferon.
    Type: Application
    Filed: May 19, 2004
    Publication date: December 14, 2006
    Applicant: Viragen, Inc
    Inventor: Karen Jervis
  • Patent number: 6433144
    Abstract: This invention relates to methods for isolating highly purified mixtures of natural Type I interferon from white blood cells. The invention also relates to highly-purified mixtures of Type I interferon which resemble natural Type I interferon in that the highly purified mixtures of natural Type I interferon includes at least 9 subtypes, i.e., alpha-1, alpha-2, alpha-5, alpha-7, alpha-8, alpha-10, alpha-14, alpha-21 and omega, giving rise to at least 16, and possibly 20 or more molecular species, including alpha-1a, alpha-1new, alpha-2a, alpha-2b, alpha-2c, alpha-5, alpha-5LG, alpha-7, alpha-8a, alpha-8c, alpha-10a, alpha-14a, alphal4-b, alpha 14-c, alpha-14LG, alpha-21a, alpha-21b, alpha-21c, omega and omega LG.
    Type: Grant
    Filed: January 12, 1999
    Date of Patent: August 13, 2002
    Assignee: Viragen, Inc.
    Inventors: Joseph P. Morris, Duy Nguyen, James Kappelman, Michael D. Potter, Mead M. McCabe, Reza Ziai, Stephen Feldman, Hipolito Hartman
  • Patent number: 6350589
    Abstract: This invention relates to methods for isolating highly-purified mixtures of natural type I interferons from white blood cells. The invention also relates to highly-purified mixtures of natural type I interferons which resemble natural type I interferon in that it includes 9 subtypes, i.e., alpha-1, alpha-2, alpha-5, alpha-7, alpha-8, alpha-10, alpha-14, alpha-21 and omega, giving rise to possibly 20 molecular species, including alpha-1a, alpha-1new, alpha-2a, alpha-2b, alpha-2c, alpha-5, alpha-5LG, alpha-7, alpha-8a, alpha-8c, alpha-10a, alpha-14a, alpha14-b, alpha 14-c, alpha-14LG, alpha-21a, alpha-21b, alpha-21c, omega and omega LG.
    Type: Grant
    Filed: December 31, 1998
    Date of Patent: February 26, 2002
    Assignee: Viragen, Inc.
    Inventors: Joseph P. Morris, Duy Nguyen, James Kappelman, Michael D. Potter, Mead M. McCabe, Reza Ziai, Stephen B. Feldman, Hipolito Hartman
  • Patent number: 5434249
    Abstract: A method for modulating the specific activitiy of a target protein which is being purified. A controller protein is added to the target protein prior to conducting a final purification step in a purification process.
    Type: Grant
    Filed: May 27, 1992
    Date of Patent: July 18, 1995
    Assignee: Viragen Inc.
    Inventors: Dana B. Jacobs, David C. Munch
  • Patent number: 4435384
    Abstract: A topical composition including transfer factor for dermatological treatment is provided. The composition may be used for cosmetic purposes and for treatment of skin lesions, such as blemishes, acne, herpes simplex, condyloma and the like. The treatment includes application of the topical composition to the infected sites.
    Type: Grant
    Filed: April 30, 1982
    Date of Patent: March 6, 1984
    Assignee: Viragen, Inc.
    Inventor: Stanley L. Warren